PLx Pharma, Inc. (PLXP): Price and Financial Metrics


PLx Pharma, Inc. (PLXP): $0.34

-0.01 (-3.97%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PLXP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PLXP POWR Grades

  • PLXP scores best on the Sentiment dimension, with a Sentiment rank ahead of 60.12% of US stocks.
  • The strongest trend for PLXP is in Growth, which has been heading up over the past 164 days.
  • PLXP's current lowest rank is in the Quality metric (where it is better than 2.44% of US stocks).

PLXP Stock Summary

  • PLXP has a higher market value than just 3.71% of US stocks; more precisely, its current market capitalization is $10,489,569.
  • For PLXP, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
  • The volatility of PLX PHARMA INC's share price is greater than that of 96.77% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to PLX PHARMA INC, a group of peers worth examining would be PESI, XTNT, TREE, SNOA, and MICT.
  • PLXP's SEC filings can be seen here. And to visit PLX PHARMA INC's official web site, go to plxpharma.com.

PLXP Valuation Summary

  • PLXP's EV/EBIT ratio is 0.6; this is 93.02% lower than that of the median Healthcare stock.
  • PLXP's EV/EBIT ratio has moved up 26.5 over the prior 106 months.

Below are key valuation metrics over time for PLXP.

Stock Date P/S P/B P/E EV/EBIT
PLXP 2022-11-25 2.2 1 -0.4 0.6
PLXP 2022-11-23 2.3 1 -0.4 0.6
PLXP 2022-11-22 2.3 1 -0.4 0.6
PLXP 2022-11-21 2.2 1 -0.4 0.6
PLXP 2022-11-18 2.1 1 -0.4 0.6
PLXP 2022-11-17 2.2 1 -0.4 0.6

PLXP Growth Metrics

    Its year over year net income to common stockholders growth rate is now at -58.65%.
  • The 2 year cash and equivalents growth rate now stands at 465.32%.
  • Its 2 year net cashflow from operations growth rate is now at -239.88%.
PLXP's revenue has moved up $3,978,436 over the prior 33 months.

The table below shows PLXP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 4.5439 -59.33534 -27.57767
2022-06-30 10.774 -57.35088 -40.72317
2022-03-31 10.291 -44.72894 -47.57222
2021-12-31 8.208 -32.118 -48.65
2021-09-30 6.6161 -21.27666 -60.70349
2021-06-30 0 -15.40224 -42.68728

PLXP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PLXP has a Quality Grade of C, ranking ahead of 39.31% of graded US stocks.
  • PLXP's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • HSTO, ABBV, and AGTC are the stocks whose asset turnover ratios are most correlated with PLXP.

The table below shows PLXP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA 361.591
2021-03-31 0.001 1 162.554
2020-12-31 0.002 1 82.828
2020-09-30 0.003 1 -48.371
2020-06-30 0.005 1 -6.788
2020-03-31 0.012 1 -5.712

PLXP Price Target

For more insight on analysts targets of PLXP, see our PLXP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.50 Average Broker Recommendation 1.5 (Moderate Buy)

PLXP Stock Price Chart Interactive Chart >

Price chart for PLXP

PLXP Price/Volume Stats

Current price $0.34 52-week high $10.53
Prev. close $0.35 52-week low $0.30
Day low $0.33 Volume 164,300
Day high $0.35 Avg. volume 273,297
50-day MA $0.53 Dividend yield N/A
200-day MA $2.23 Market Cap 9.79M

PLx Pharma, Inc. (PLXP) Company Bio


PLx Pharma, Inc. is a late-stage specialty pharmaceutical company developing aspirin products that use its patented drug delivery system, which targets delivery of APIs to various portions of the gastrointestinal tract. This has the potential to improve the absorption of many drugs and to reduce acute GI side effects associated with aspirin and ibuprofen, and potentially other drugs.


PLXP Latest News Stream


Event/Time News Detail
Loading, please wait...

PLXP Latest Social Stream


Loading social stream, please wait...

View Full PLXP Social Stream

Latest PLXP News From Around the Web

Below are the latest news stories about PLX PHARMA INC that investors may wish to consider to help them evaluate PLXP as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off the day with a look at the biggest pre-market stock movers that traders will want to know about for Tuesday morning!

William White on InvestorPlace | November 15, 2022

Analysts Offer Insights on Healthcare Companies: PLx Pharma (PLXP) and BioCardia (BCDA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PLx Pharma (PLXP – Research Report) and BioCardia (BCDA – Research Report). PLx Pharma (PLXP) JMP Securities analyst Jason Butler reiterated a Hold rating on PLx Pharma today. The company's shares closed last Friday at $0.41. According to TipRanks.

Christine Brown on TipRanks | November 11, 2022

PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 15.91% and 35.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($

Yahoo | November 10, 2022

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 9.53% and 0.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

Read More 'PLXP' Stories Here

PLXP Price Returns

1-mo -43.89%
3-mo -59.09%
6-mo -84.47%
1-year -96.36%
3-year -93.02%
5-year -94.79%
YTD -95.76%
2021 45.11%
2020 26.32%
2019 185.62%
2018 -77.83%
2017 -46.09%

Continue Researching PLXP

Want to see what other sources are saying about PLx Pharma Inc's financials and stock price? Try the links below:

PLx Pharma Inc (PLXP) Stock Price | Nasdaq
PLx Pharma Inc (PLXP) Stock Quote, History and News - Yahoo Finance
PLx Pharma Inc (PLXP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6351 seconds.